|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Adaptive Biotechnologies Corp. 10-K 12/31/23 96:15M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.53M
2: EX-23.1 Consent of Expert or Counsel HTML 28K
7: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 56K
Awarded Compensation
3: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
9: R1 Document and Entity Information HTML 100K
10: R2 Consolidated Balance Sheets HTML 160K
11: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
12: R4 Consolidated Statements of Operations HTML 107K
13: R5 Consolidated Statements of Comprehensive Loss HTML 57K
14: R6 Consolidated Statements of Shareholders' Equity HTML 82K
15: R7 Consolidated Statements of Cash Flows HTML 116K
16: R8 Organization and Description of Business HTML 33K
17: R9 Significant Accounting Policies HTML 110K
18: R10 Revenue HTML 89K
19: R11 Deferred Revenue HTML 39K
20: R12 Fair Value Measurements HTML 90K
21: R13 Investments HTML 101K
22: R14 Property and Equipment, Net HTML 56K
23: R15 Goodwill and Intangible Assets HTML 68K
24: R16 Accrued Liabilities HTML 51K
25: R17 Leases HTML 76K
26: R18 Revenue Interest Purchase Agreement HTML 60K
27: R19 Commitments and Contingencies HTML 33K
28: R20 Shareholders' Equity HTML 47K
29: R21 Equity Incentive Plans HTML 154K
30: R22 Microsoft Collaboration Agreement HTML 37K
31: R23 Restructuring HTML 33K
32: R24 Income Taxes HTML 123K
33: R25 Net Loss Per Share Attributable to Adaptive HTML 68K
Biotechnologies Corporation Common Shareholders
34: R26 Retirement Plan HTML 32K
35: R27 Significant Accounting Policies (Policies) HTML 176K
36: R28 Significant Accounting Policies (Tables) HTML 54K
37: R29 Revenue (Tables) HTML 61K
38: R30 Deferred Revenue (Tables) HTML 36K
39: R31 Fair Value Measurements (Tables) HTML 88K
40: R32 Investments (Tables) HTML 98K
41: R33 Property and Equipment, Net (Tables) HTML 53K
42: R34 Goodwill and Intangible Assets (Tables) HTML 69K
43: R35 Accrued Liabilities (Tables) HTML 50K
44: R36 Leases (Tables) HTML 55K
45: R37 Revenue Interest Purchase Agreement (Tables) HTML 43K
46: R38 Shareholders' Equity (Tables) HTML 36K
47: R39 Equity Incentive Plans (Tables) HTML 139K
48: R40 Income Taxes (Tables) HTML 118K
49: R41 Net Loss Per Share Attributable to Adaptive HTML 69K
Biotechnologies Corporation Common Shareholders
(Tables)
50: R42 Significant Accounting Policies - Additional HTML 52K
Information (Details)
51: R43 Significant Accounting Policies - Schedule of HTML 41K
Concentrations of Risk Percentage (Details)
52: R44 Significant Accounting Policies - Summary of HTML 44K
Useful Lives Assigned to Property and Equipment
(Details)
53: R45 Revenue - Schedule of Disaggregated Revenue HTML 47K
(Details)
54: R46 Revenue - Additional Information (Details) HTML 67K
55: R47 Deferred Revenue - Additional Information HTML 41K
(Details)
56: R48 Deferred Revenue - Additional Information HTML 35K
(Details1)
57: R49 Deferred Revenue - Schedule of Changes in Deferred HTML 35K
Revenue (Details)
58: R50 Fair Value Measurements - Summary of Financial HTML 51K
Assets and Liabilities Measured at Fair Value on a
Recurring Basis (Details)
59: R51 Investments - Schedule of Available-for-sale HTML 51K
Investments (Details)
60: R52 Investments - Additional Information (Details) HTML 35K
61: R53 Investments - Schedule of Gross Unrealized Holding HTML 39K
Losses and Fair Values for Investments in
Unrealized Loss Position (Details)
62: R54 Property and Equipment, Net - Schedule of Property HTML 49K
and Equipment (Details)
63: R55 Property and Equipment, Net - Additional HTML 30K
Information (Details)
64: R56 Goodwill and Intangible Assets - Additional HTML 36K
Information (Details)
65: R57 Goodwill and Intangible Assets - Summary of HTML 41K
Intangible Assets Subject to Amortization
(Details)
66: R58 Goodwill and Intangible Assets - Schedule of HTML 39K
Future Amortization Expense for Intangible Assets
(Details)
67: R59 Accrued Liabilities - Schedule of Accrued HTML 44K
Liabilities (Details)
68: R60 Leases- Additional Information (Details) HTML 106K
69: R61 Leases- Summary of Other Information Related to HTML 32K
Operating Lease (Details)
70: R62 Leases- Summary of Reconciles Undiscounted HTML 51K
Operating Lease Cash Flows (Details)
71: R63 Revenue Interest Purchase Agreement - Additional HTML 64K
Information (Details)
72: R64 Revenue Interest Purchase Agreement - Schedule of HTML 42K
Revenue Interest Liability, Net Activity (Details)
73: R65 Shareholders' Equity - Additional Information HTML 52K
(Details)
74: R66 Shareholders' Equity - Summary of Reserved Shares HTML 44K
of Common Stock (Details)
75: R67 Equity Incentive Plans - Additional Information HTML 109K
(Details)
76: R68 Equity Incentive Plans - Summary of Changes in HTML 46K
Shares Available for Grant (Details)
77: R69 Equity Incentive Plans - Summary of Stock Option HTML 62K
Activity Under 2009 Plan and 2019 Plan (Details)
78: R70 Equity Incentive Plans - Summary of Restricted HTML 56K
Stock Unit Activity (Details)
79: R71 Equity Incentive Plans - Summary of Estimated HTML 55K
Grant Date Fair Values of Stock Options Granted
(Details)
80: R72 Equity incentive Plans - Summary of Compensation HTML 48K
Costs Related to Stock Options and RSUS Included
on Consolidated Statements of Operations (Details)
81: R73 Equity Incentive Plans - Schedule of Unrecognized HTML 47K
Share-Based Compensation Expense and the Remaining
Weighted-Average Recognition Period (Details)
82: R74 Microsoft Collaboration Agreement - Additional HTML 39K
Information (Details)
83: R75 Restructuring - Additional Information (Details) HTML 35K
84: R76 Income Taxes - Schedule of Components of Loss HTML 37K
Before Provision for Income Taxes (Details)
85: R77 Income Taxes - Schedule of Deferred Tax Assets and HTML 56K
Liabilities (Details)
86: R78 Income Taxes - Additional Information (Details) HTML 50K
87: R79 Income Taxes - Schedule of Reconciliation of HTML 48K
Effective Tax Rate of Provision for Income Taxes
Differs from Federal Statutory Rate (Detail)
88: R80 Income Taxes - Schedule of Change In Unrecognized HTML 32K
Tax Benefits (Detail)
89: R81 Net Loss Per Share Attributable to Adaptive HTML 58K
Biotechnologies Corporation Common Shareholders -
Computation of the Basic and Diluted Net Loss Per
Share Attributable to Common Shareholders
(Details)
90: R82 Net Loss Per Share Attributable to Adaptive HTML 41K
Biotechnologies Corporation Common Shareholders -
Weighted-Average Common Stock Equivalents were
Excluded From Calculation of Diluted Net Loss Per
Share (Details)
91: R83 Retirement Plan - Additional Information (Details) HTML 33K
93: XML IDEA XML File -- Filing Summary XML 186K
96: XML XBRL Instance -- adpt-20231231_htm XML 2.38M
92: EXCEL IDEA Workbook of Financial Report Info XLSX 134K
8: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 3.99M
Linkbases Document -- adpt-20231231
94: JSON XBRL Instance as JSON Data -- MetaLinks 586± 881K
95: ZIP XBRL Zipped Folder -- 0000950170-24-023095-xbrl Zip 1.40M
 | Download this zipped .zip folder |
| Files: | adpt-20231231.htm adpt-20231231.xsd adpt-ex23_1.htm adpt-ex31_1.htm adpt-ex31_2.htm adpt-ex32_1.htm adpt-ex32_2.htm adpt-ex97_1.htm img63237988_0.jpg img63237988_1.jpg img63237988_2.jpg img63237988_3.jpg img63237988_4.jpg img63237988_5.jpg img63237988_6.jpg |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/14/23 Adaptive Biotechnologies Corp. 10-K 12/31/22 102:31M Donnelley … Solutions/FA 9/12/22 Adaptive Biotechnologies Corp. 8-K:1,2,8,9 9/12/22 12:1M ActiveDisclosure/FA 5/04/22 Adaptive Biotechnologies Corp. 10-Q 3/31/22 76:8.2M ActiveDisclosure/FA 2/24/21 Adaptive Biotechnologies Corp. 10-K 12/31/20 98:18M ActiveDisclosure/FA 8/10/20 Adaptive Biotechnologies Corp. 10-Q 6/30/20 75:9.3M ActiveDisclosure/FA 2/26/20 Adaptive Biotechnologies Corp. 10-K 12/31/19 93:14M ActiveDisclosure/FA 8/13/19 Adaptive Biotechnologies Corp. 10-Q 6/30/19 78:10M ActiveDisclosure/FA 8/07/19 Adaptive Biotechnologies Corp. 8-K:1,7,9 8/02/19 4:1.4M Donnelley … Solutions/FA 7/01/19 Adaptive Biotechnologies Corp. 8-K:5,8,9 6/26/19 5:254K Donnelley … Solutions/FA 6/17/19 Adaptive Biotechnologies Corp. S-1/A 10:5.4M Donnelley … Solutions/FA 5/30/19 Adaptive Biotechnologies Corp. S-1 22:10M Donnelley … Solutions/FA |